We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+37.81%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.66B
AUM Growth
+$539M
Cap. Flow
-$225M
Cap. Flow %
-4.83%
Top 10 Hldgs %
41.2%
Holding
160
New
26
Increased
26
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$372M
2
KRON
Kronos Bio
KRON
+$41.3M
3
SQZ
SQZ Biotechnologies Company
SQZ
+$41M
4
Z icon
Zillow
Z
+$38.7M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$71.8M
2
BABA icon
Alibaba
BABA
+$62.5M
3
MRNA icon
Moderna
MRNA
+$25.3M
4
STNE icon
StoneCo
STNE
+$21.2M
5
SRRK icon
Scholar Rock
SRRK
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 77.21%
2 Consumer Discretionary 9.12%
3 Technology 2.01%
4 Communication Services 1.85%
5 Real Estate 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$362M 7.76%
14,818,300
– –
SEER icon
2
Seer Inc
SEER
$115M
$328M 7.04%
+5,840,911
New +$372M
ONC
3
BeOne Medicines Ltd
ONC
$34B
$258M 5.55%
1,000,000
+100,000
+11% +$27.5M
LXRX icon
4
Lexicon Pharmaceuticals
LXRX
$1.03B
$243M 5.23%
71,178,364
+10,937,500
+18% +$20.9M
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$179M 3.85%
1,400,000
– –
FATE icon
6
Fate Therapeutics
FATE
$277M
$127M 2.73%
1,400,000
-100,000
-7% -$6.21M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$110M 2.36%
500,000
– –
IGMS
8
DELISTED
IGM Biosciences
IGMS
$106M 2.27%
1,200,000
+511,090
+74% +$35.9M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$38.1B
$104M 2.23%
800,000
– –
SRRK icon
10
Scholar Rock
SRRK
$5.9B
$102M 2.19%
2,100,000
-395,140
-16% -$14.3M
GDS icon
11
GDS Holdings
GDS
$6.05B
$93.6M 2.01%
1,000,000
– –
KLRS
12
Kalaris Therapeutics
KLRS
$81.1M
$89.3M 1.92%
101,016
– –
ARGX icon
13
argenx
ARGX
$55.2B
$88.2M 1.89%
300,000
-24,200
-7% -$6.65M
ABBV icon
14
CALL
AbbVie
ABBV
$470B
$85.7M 1.84%
800,000
+300,000
+60% +$28.8M
BNTX icon
15
BioNTech
BNTX
$23.6B
$81.5M 1.75%
1,000,000
-731,214
-42% -$71.8M
GBIO
16
DELISTED
Generation Bio
GBIO
$79.8M 1.71%
281,419
– –
TGTX icon
17
TG Therapeutics
TGTX
$8.34B
$78M 1.68%
1,500,000
– –
Z icon
18
Zillow
Z
$7.86B
$71.4M 1.53%
550,000
+350,000
+175% +$38.7M
SDGR icon
19
Schrodinger
SDGR
$1.14B
$63.1M 1.36%
797,445
-100,000
-11% -$6.29M
BMY icon
20
CALL
Bristol-Myers Squibb
BMY
$130B
$62M 1.33%
+1,000,000
New +$61.5M
BEKE icon
21
KE Holdings
BEKE
$17.7B
$61.5M 1.32%
1,000,000
+130,000
+15% +$8.64M
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$57.7M 1.24%
2,500,000
-500,000
-17% -$10.2M
MORF
23
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$55.4M 1.19%
1,651,686
– –
ATRA icon
24
Atara Biotherapeutics
ATRA
$73.1M
$55M 1.18%
112,000
+22,000
+24% +$10.2M
BDTX icon
25
Black Diamond Therapeutics
BDTX
$96.8M
$52.8M 1.13%
1,646,517
+125,000
+8% +$4.11M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2020 Portfolio in Review

As of Q4 2020, Artal Group held 160 positions worth $4.66B, up 13% from $4.12B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Artal Group withdrew a net $225M in Q4 2020, closing 30 positions and reducing 23 holdings. Its most notable exit was StoneCo, an estimated $21.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 57% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Seer Inc worth $328M.

  • Artal Group's largest Q4 2020 buy was Seer Inc: 5,840,911 shares worth $328M.
  • Artal Group added most to Zillow in Q4 2020, an estimated $38.7M increase.
  • Artal Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $71.8M.
  • Artal Group fully exited StoneCo in Q4 2020, selling an estimated $21.2M.
  • Artal Group's ten largest holdings make up 41% of its $4.66B portfolio in Q4 2020.
  • Artal Group opened 26 new positions and closed 30 in Q4 2020.
  • Artal Group's portfolio value rose 13% quarter-over-quarter to $4.66B.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.